Codagenix Announces Close of $25 million Extension of Series B
Funding supports continued clinical studies for pediatric RSV and universal influenza vaccine candidates as well as expanded indications for oncology vertical
FARMINGDALE, N.Y. and CAMBRIDGE, Mass., Feb. 15, 2023 -- (Healthcare Sales & Marketing Network... Biopharmaceuticals, Venture Capital Codagenix, CodaVax-RSV, respiratory syncytial virus
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Funding | Influenza | Influenza Vaccine | Marketing | Pediatrics | Pharmaceuticals | Respiratory Medicine | Study | Vaccines | Venture Capital